Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2017 (2017), Article ID 4313561, 16 pages
https://doi.org/10.1155/2017/4313561
Research Article

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ

1Shenzhen Chipscreen Biosciences Ltd., Shenzhen, Guangdong 518057, China
2Shenzhen Key Lab of Gene & Antibody Therapy, Division of Life & Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong 518057, China

Correspondence should be addressed to Xian-Ping Lu; moc.neercspihc@ulpx

Received 9 May 2017; Revised 23 July 2017; Accepted 9 August 2017; Published 19 September 2017

Academic Editor: Xinran Ma

Copyright © 2017 De-Si Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Kahn, J. M. Lachin, B. Zinman et al., “Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT,” Diabetes, vol. 60, no. 5, pp. 1552–1560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. W. L. Bennett, N. M. Maruthur, S. Singh et al., “Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations,” Annals of Internal Medicine, vol. 154, no. 9, pp. 602–618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Ji, D. Hu, C. Pan et al., “Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients,” American Journal of Medicine, vol. 126, no. 10, pp. 925–e22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. R. K. Semple, V. K. K. Chatterjee, and S. O'Rahilly, “PPARγ and human metabolic disease,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Lefebvre, G. Chinetti, J. C. Fruchart, and B. Staels, “Sorting out the roles of PPARα in energy metabolism and vascular homeostasis,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 571–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Wahli and L. Michalik, “PPARs at the crossroads of lipid signaling and inflammation,” Trends in Endocrinology and Metabolism, vol. 23, no. 7, pp. 351–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Peters, Y. M. Shah, and F. J. Gonzalez, “The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention,” Nature Reviews Cancer, vol. 12, no. 3, pp. 181–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Pourcet, J.-C. Fruchart, B. Staels, and C. Glineur, “Selective PPAR modulators, dual and pan PPAR agonists: Multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis,” Expert Opinion on Emerging Drugs, vol. 11, no. 3, pp. 379–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Gross, M. Pawlak, P. Lefebvre, and B. Staels, “PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD,” Nature Reviews Endocrinology, vol. 13, no. 1, pp. 36–49, 2016. View at Publisher · View at Google Scholar
  11. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Choi, A. S. Banks, T. M. Kamenecka et al., “Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation,” Nature, vol. 477, no. 7365, pp. 477–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Li, W. Fan, J. Xu et al., “Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity,” Cell, vol. 147, no. 4, pp. 815–826, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Weidner, J. C. de Groot, A. Prasad et al., “Amorfrutins are potent antidiabetic dietary natural products,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7257–7262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. P.-P. Li, S. Shan, Y.-T. Chen et al., “The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats,” British Journal of Pharmacology, vol. 148, no. 5, pp. 610–618, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. B. K. He, Z. Q. Ning, Z. B. Li et al., “In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist,” PPAR Research, Article ID 546548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Zhu, Y. Y. Goh, H. F. A. Chin, S. Kersten, and N. S. Tan, “Angiopoietin-like 4: a decade of research,” Bioscience Reports, vol. 32, no. 3, pp. 211–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. Sugden, M. G. Zariwala, and M. J. Holness, “PPARs and the orchestration of metabolic fuel selection,” Pharmacological Research, vol. 60, no. 3, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. M. Berman, J. Westbrook, Z. Feng et al., “The protein data bank,” Nucleic Acids Research, vol. 28, no. 1, pp. 235–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. E. F. Pettersen, T. D. Goddard, C. C. Huang et al., “UCSF Chimera—a visualization system for exploratory research and analysis,” Journal of Computational Chemistry, vol. 25, no. 13, pp. 1605–1612, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Thomsen and M. H. Christensen, “MolDock: a new technique for high-accuracy molecular docking,” Journal of Medicinal Chemistry, vol. 49, no. 11, pp. 3315–3321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. W. L. DeLano, The PyMol Users Manual , DeLano Scientific, CA, San Carlos, 2002.
  23. K. A. Burns and J. P. Vanden Heuvel, “Modulation of PPAR activity via phosphorylation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 952–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Li, M. Choi, K. Suino et al., “Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9505–9510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. K. W. Nettles, “Insights into PPARgamma from structures with endogenous and covalently bound ligands,” Nature Structural and Molecular Biology, vol. 15, no. 9, pp. 893–895, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. B. Bruning, M. J. Chalmers, S. Prasad et al., “Partial agonists activate PPARγ using a helix 12 independent mechanism,” Structure, vol. 15, no. 10, pp. 1258–1271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Koppen and E. Kalkhoven, “Brown vs white adipocytes: The PPARγ coregulator story,” FEBS Letters, vol. 584, no. 15, pp. 3250–3259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Viswakarma, Y. Jia, L. Bai et al., “Coactivators in PPAR-regulated gene expression,” PPAR Research, vol. 2010, Article ID 250126, 21 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA,” Nature, vol. 456, no. 7220, pp. 350–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Moras, “Structure of Full-Length PPARγ-RXRα: A Snapshot of a Functional Complex?” Cell Metabolism, vol. 9, no. 1, pp. 8–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Lombardi, G. Cantini, E. Piscitelli et al., “A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells,” Arteriosclerosis Thrombosis and Vascular Biology, vol. 28, no. 4, pp. 718–724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. E. Nissen and K. Wolski, “Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality,” Archives of Internal Medicine, vol. 170, no. 14, pp. 1191–1201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Hillaire-Buys, J.-L. Faillie, and J.-L. Montastruc, “Pioglitazone and bladder cancer,” The Lancet, vol. 378, no. 9802, pp. 1543-1544, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. F. M. Gregoire, F. Zhang, H. J. Clarke et al., “MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema,” Molecular Endocrinology, vol. 23, no. 7, pp. 975–988, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. S. Higgins and C. S. Mantzoros, “The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer,” PPAR Research, vol. 2008, Article ID 936906, 9 pages, 2008. View at Publisher · View at Google Scholar
  36. Y. Li, Z. Wang, N. Furukawa et al., “T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor γ binding properties,” The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9168–9176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. R. Henry, A. M. Lincoff, S. Mudaliar, M. Rabbia, C. Chognot, and M. Herz, “Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study,” The Lancet, vol. 374, no. 9684, pp. 126–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. A. Amato, S. Rajagopalan, and J. Z. Lin, “GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain,” The Journal of Biological Chemistry, vol. 287, no. 33, pp. 28169–28179, 2012. View at Publisher · View at Google Scholar
  39. D. Jones, “Potential remains for PPAR-targeted drugs,” Nature Reviews Drug Discovery, vol. 9, no. 9, pp. 668-669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. T. S. Hughes, M. J. Chalmers, S. Novick et al., “Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism,” Structure, vol. 20, no. 1, pp. 139–150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Yu and H. E. Xu, “Couple dynamics: PPARγ and its ligand partners,” Structure, vol. 20, no. 1, pp. 2–4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. R. R. V. Malapaka, S. Khoo, J. Zhang et al., “Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors,” The Journal of Biological Chemistry, vol. 287, no. 1, pp. 183–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Bugge, L. Grøntved, M. M. Aagaard, R. Borup, and S. Mandrup, “The PPARγ2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment,” Molecular Endocrinology, vol. 23, no. 6, pp. 794–808, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Alex, K. Lange, and T. Amolo, “Short chain fatty acids stimulate Angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating, A-?” Molecular Cellular Biology, vol. 33, no. 7, p. pp, 2013. View at Google Scholar
  45. R. B. Goldberg, D. M. Kendall, M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Orasanu, O. Ziouzenkova, P. R. Devchand et al., “The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice,” Journal of the American College of Cardiology, vol. 52, no. 10, pp. 869–881, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Guilherme, J. V. Virbasius, V. Puri, and M. P. Czech, “Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes,” Nature Reviews Molecular Cell Biology, vol. 9, no. 5, pp. 367–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Karpe, J. R. Dickmann, and K. N. Frayn, “Fatty acids, obesity, and insulin resistance: time for a reevaluation,” Diabetes, vol. 60, no. 10, pp. 2441–2449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Georgiadi, L. Lichtenstein, T. Degenhardt et al., “Induction of cardiac angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor β/δ and protects against fatty acid-induced oxidative stress,” Circulation Research, vol. 106, no. 11, pp. 1712–1721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. O. Osborn, D. D. Sears, and J. M. Olefsky, “Fat-induced inflammation unchecked,” Cell Metabolism, vol. 12, no. 6, pp. 553-554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Bird, “Macrophages: Preventing lipid overload,” Nature Reviews Immunology, vol. 11, no. 2, p. 73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Romeo, L. A. Pennacchio, Y. Fu et al., “Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL,” Nature Genetics, vol. 39, no. 4, pp. 513–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Xu, M. C. Lam, K. W. Chan et al., “Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6086–6091, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Köster, Y. B. Chao, M. Mosior et al., “Transgenic angiopoietin-like (Angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3: Regulation of triglyceride metabolism,” Endocrinology, vol. 146, no. 11, pp. 4943–4950, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Georgiadi, Y. Wang, and R. Stienstra, “Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development,” Arteriosclerosis Thrombosis Vascular Biology, vol. 33, no. 7, pp. 1529–1537, 2013. View at Publisher · View at Google Scholar
  56. X. Yu, S. C. Burgess, H. Ge et al., “Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 5, pp. 1767–1772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Lichtenstein, J. F. P. Berbée, S. J. van Dijk et al., “Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2420–2427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, “Myocardial fatty acid metabolism in health and disease,” Physiological Reviews, vol. 90, no. 1, pp. 207–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. A. Deeg, J. B. Buse, R. B. Goldberg et al., “Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 30, no. 10, pp. 2458–2464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Chokkalingam, K. Jewell, L. Norton et al., “High-fat/low-carbohydrate diet reduces insulin-stimulated carbohydrate oxidation but stimulates nonoxidative glucose disposal in humans: An important role for skeletal muscle pyruvate dehydrogenase kinase 4,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 284–292, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. N. H. Jeoung, P. Wu, M. A. Joshi et al., “Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvation,” Biochemical Journal, vol. 397, no. 3, pp. 417–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Zhao, H. J. Nam, S. C. Burgess et al., “Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 294, no. 2, pp. H936–H943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. K. T. Chambers, T. C. Leone, N. Sambandam et al., “Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response,” Journal of Biological Chemistry, vol. 286, no. 13, pp. 11155–11162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Publisher · View at Google Scholar · View at Scopus